NCT01162252

Brief Summary

The purpose of the study is to examine and compare the effects of the Mindfulness-Based Stress Reduction (MBSR) program and the Living Well (LW) program on adults with psoriasis in terms of how these programs may affect their psoriasis, immune function, physical and emotional health, and well-being.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
130

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Mar 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

June 21, 2010

Completed
23 days until next milestone

First Posted

Study publicly available on registry

July 14, 2010

Completed
3.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2013

Completed
Last Updated

August 13, 2014

Status Verified

August 1, 2014

Enrollment Period

3.8 years

First QC Date

June 21, 2010

Last Update Submit

August 12, 2014

Conditions

Keywords

psoriasismindfulnessMBSRstressliving well

Outcome Measures

Primary Outcomes (1)

  • Psoriasis disease severity measured from biopsied tissue samples of psoriatic and nonpsoriatic skin.

    Psoriasis is assessed for keratinocyte proliferation including immunohistochemistry (for CD3, neutrophil elastase, keratin 6 and S100A7 markers) and quantitative real time polymerase chain reaction (qRT-PCR) to examine expression of mRNA for IFN-γ, TNF-α, IL-17A, and the shared p40 subunit of IL-12 and IL-23 (assessed pre \& post intervention).

    8 weeks

Secondary Outcomes (3)

  • Immunological markers of inflammation measured from blood samples.

    16 weeks

  • Perceived Stress Scale (Cohen S., Kamarck T., & Mermelstein R. (1983))

    16 weeks

  • State-Trait Anxiety Inventory (Spielberger C.D., Gorsuch R.L., & Lushene R.E. (1970))

    16 weeks

Study Arms (2)

Mindfulness-Based Stress Reduction

ACTIVE COMPARATOR
Behavioral: Mindfulness-Based Stress Reduction

Living Well

ACTIVE COMPARATOR
Behavioral: Living Well

Interventions

The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.

Also known as: MBSR
Mindfulness-Based Stress Reduction
Living WellBEHAVIORAL

The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.

Also known as: LW
Living Well

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 and older
  • English speaking
  • Clinical diagnosis of psoriasis (active at initial visit)

You may not qualify if:

  • currently receiving immunosuppressive therapy for cancer or for diseases unrelated to psoriasis (or \< 6 months post-chemo or radiation)
  • major, uncorrected sensory impairments
  • cognitive deficits (MMSE \<25, or deficits deemed significant enough to interfere)
  • severe cardiovascular disease
  • current alcohol abuse or non-alcohol psychoactive substance use disorders, psychotic disorders (current and lifetime), and current mood disorder with psychotic features.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Rochester; University Dermatology Associates

Rochester, New York, 14623, United States

Location

Related Links

MeSH Terms

Conditions

Psoriasis

Interventions

Mindfulness-Based Stress Reduction

Condition Hierarchy (Ancestors)

Skin Diseases, PapulosquamousSkin DiseasesSkin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

MindfulnessCognitive Behavioral TherapyBehavior TherapyPsychotherapyBehavioral Disciplines and Activities

Study Officials

  • Jan A Moynihan, PhD

    University of Rochester

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Director, The Rochester Center for Mind-Body Research

Study Record Dates

First Submitted

June 21, 2010

First Posted

July 14, 2010

Study Start

March 1, 2010

Primary Completion

December 1, 2013

Study Completion

December 1, 2013

Last Updated

August 13, 2014

Record last verified: 2014-08

Locations